Latest "Galectin Therapeutics" News Stories

21:21 EST 2nd December 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 6,800+

Extremely Relevant

Galectin Therapeutics Inc. (GALT) Stock Rating Lowered by Zacks Investment Research

According to Zacks, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function.

BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with...

Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv. “While we are expect that the 30-patient placebo-controlled Phase 2 study will [&...

Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical ...

Dr. Traber to speak on Galectin Therapeutics’ Development of GR-MD-02 for treatment of human disease Read more...

Galectin tanks as NASH drug candidate fails in study of patients with advanced fibrosis

Galectin Therapeutics has reported disappointing results from a mid-stage study of its candidate compound…

BRIEF-Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data

* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:

Psoriasis improvement not sufficient to continue says Galectin

Galectin Therapeutics Inc (NASDAQ:GALT) won’t pursue GR-MD-02 as a drug for psoriasis after patients in a small trial did not show the required improvement.   The drug developer added, however, that the results did give it encouragement for its liver fibrosis program, which is the drug’s primary focus.   Galectin started the small study after a patient taking the drug in a tr...

Galectin Therapeutics, Inc. formerly ProPharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

Project Synopsis:Datamonitor's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.Project Description:Datamonitors' Galectin Therapeutics, Inc. formerly ProPharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Allianc...


RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways

BBI Solutions launches new range of antibodies for Galectin-3 biomarker

BBI Solutions has announced the launch of a range of antibodies for the biomarker Galectin-3. The antibodies complement BBI’s Galectin-3 antigen, which was also launched earlier this year.

A Major Catalyst Awaits Galectin Therapeutics Next Week

Galectin Therapeutics Presents At The MicroCap Plus Conference - Slide Show

Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of ...


Galectin plunges after miss in exploratory NASH trial

Shares in the biotech nearly halved in value Wednesday, as investors soured on the potential of Galectin's lead drug after it failed to hit its goal in a Phase 2a study. 

Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017. “We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original […]

Unexpected Properties of Galectin-3

The new study examines the biomechanics of galectin-3's interaction with glycosaminoglycans (GAG) and proteoglycans. Tarun Dam, an associate professor of chemistry at Michigan Technological University, led the study. The other co-authors of the paper are graduate students Melanie Talaga, Ni Fan, ...

BRIEF-Galectin says announces top-line data from exploratory phase 2A pilot trial (NASH-FX)

* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis

Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update

Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property franchise NORCROSS, Ga., Aug. 09, 2016 (GLOBE NEWSWIRE) Read more...

BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing

* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing

Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) ...

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) Read more...

Galectin suffers blow as NASH trial fails

As big pharma races to develop a treatment for the liver disease non-alcoholic steatohepatitis (NASH), biotech Galectin suffered a blow as its potential treatment failed in a mid-stage clinical trial. Galectin said its phase 2a NASH-FX trial evaluating GR-MD-02 in 30 NASH patients with advanced fibrosis failed to meet its endpoint. The exploratory four month long randomised study did not meet it...

Galectin Therapeutics, Inc. GALT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryGalectin Therapeutics, Inc. Galectin Therapeutics is a biotechnology company that offers therapies. The company discovers, develops and commercializes therapies for fibrotic disease and cancer. Its products include GRMD02 and GMCT01. The company's GRMD02 is a drug candidate used in the treatment of fibrotic liver disease. Galectin Therapeutics's GMCT01 is a vaccine used to treat patients wi...

Sugar-binding protein galectin-9 found to be a new weapon to cure HIV

The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped. These latent, HIV-infected cells are untouched by antiretroviral therapy and are unseen by the immune system. Moving medicine closer to a cure for HIV, scientists at Blood Systems Research Institute (BSRI), the Univ...

Galectin-4 (LGALS4)

Patient sample, cell culture and mouse studies suggest inhibiting

Quick Search

News Quicklinks